ADMA Biologics shareholders elect three Class II directors and ratify auditor at 2024 annual meeting

ADMA BIOLOGICS, INC.

Steven A. Elms, Adam S. Grossman, Young T. Kwon elected as Class II directors with 71%, 97%, 98% of votes cast excluding broker non-votes.
Ratification of CohnReznick LLP as independent auditor for FY2024 approved with 184.5M for, 2.0M against, 0.2M abstain.
Annual meeting quorum achieved with 186.7M shares represented out of 231.8M outstanding (80.5% of shares).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.